TASMAR Drug Patent Profile
✉ Email this page to a colleague
When do Tasmar patents expire, and when can generic versions of Tasmar launch?
Tasmar is a drug marketed by Bausch and is included in one NDA.
The generic ingredient in TASMAR is tolcapone. There are five drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the tolcapone profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Tasmar
A generic version of TASMAR was approved as tolcapone by PAR PHARM INC on March 26th, 2015.
Summary for TASMAR
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 108 |
Clinical Trials: | 19 |
Patent Applications: | 5,522 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for TASMAR |
What excipients (inactive ingredients) are in TASMAR? | TASMAR excipients list |
DailyMed Link: | TASMAR at DailyMed |
Recent Clinical Trials for TASMAR
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Chicago | Phase 2 |
University of Colorado, Denver | Phase 2 |
Corino Therapeutics, Inc. | Early Phase 1 |
Pharmacology for TASMAR
Drug Class | Catechol-O-Methyltransferase Inhibitor |
Mechanism of Action | Catechol O-Methyltransferase Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for TASMAR
US Patents and Regulatory Information for TASMAR
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bausch | TASMAR | tolcapone | TABLET;ORAL | 020697-001 | Jan 29, 1998 | AB | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
Bausch | TASMAR | tolcapone | TABLET;ORAL | 020697-002 | Jan 29, 1998 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for TASMAR
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Bausch | TASMAR | tolcapone | TABLET;ORAL | 020697-001 | Jan 29, 1998 | ⤷ Try a Trial | ⤷ Try a Trial |
Bausch | TASMAR | tolcapone | TABLET;ORAL | 020697-001 | Jan 29, 1998 | ⤷ Try a Trial | ⤷ Try a Trial |
Bausch | TASMAR | tolcapone | TABLET;ORAL | 020697-002 | Jan 29, 1998 | ⤷ Try a Trial | ⤷ Try a Trial |
Bausch | TASMAR | tolcapone | TABLET;ORAL | 020697-002 | Jan 29, 1998 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for TASMAR
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Viatris Healthcare Limited | Tasmar | tolcapone | EMEA/H/C/000132 Tasmar is indicated in combination with levodopa / benserazide or levodopa / carbidopa for use in patients with levodopa-responsive idiopathic Parkinson’s disease and motor fluctuations, who failed to respond to or are intolerant of other catechol-O-methyltransferase (COMT) inhibitors.Because of the risk of potentially fatal, acute liver injury, Tasmar should not be considered as a first-line adjunct therapy to levodopa / benserazide or levodopa / carbidopa.Since Tasmar should be used only in combination with levodopa / benserazide and levodopa / carbidopa, the prescribing information for these levodopa preparations is also applicable to their concomitant use with Tasmar. |
Authorised | no | no | no | 1997-08-27 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for TASMAR
See the table below for patents covering TASMAR around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
South Korea | 930001054 | ⤷ Try a Trial | |
Luxembourg | 90219 | ⤷ Try a Trial | |
Ireland | 61316 | 3,5-disubstituted pyrocatechol derivatives | ⤷ Try a Trial |
Czechoslovakia | 9104022 | ⤷ Try a Trial | |
Ireland | 870609 | ⤷ Try a Trial | |
Netherlands | 970041 | ⤷ Try a Trial | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for TASMAR
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0237929 | C970041 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: TOLCAPON; REGISTRATION NO/DATE: EU/1/97/044/001-6 19970827 |
0237929 | 97C0112 | Belgium | ⤷ Try a Trial | PRODUCT NAME: TOLCAPONE; REGISTRATION NO/DATE: EU/1/97/044/001 19970827 |
0237929 | 68/1997 | Austria | ⤷ Try a Trial | PRODUCT NAME: TOLCAPONE; REGISTRATION NO/DATE: EU/1/97/044/001 - EU/1/97/044/006 19970827 |
0237929 | SPC/GB97/088 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: TOLCAPONE; REGISTERED: CH 54055/01 19970225; CH 54055/02 19970225; UK EU/1/97/044/001 19970827; UK EU/1/97/044/002 19970827; UK EU/1/97/044/003 19970827; UK EU/1/97/044/004 19970827; UK EU/1/97/044/005 19970827; UK EU/1/97/044/006 19970827 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |